Try our Advanced Search for more refined results
Life Sciences - December, 2024
185 articles
- Ex-Pharma Exec Charged With $38M Insider Trading Scheme
- HHS Can't Enforce Abortion Privacy Rule Against Texas Doctor
- Sens. Aim To Protect Generics With Skinny Labels In New Bill
- South Korean Needle Operation Secures Patent Win At ITC
- Fed. Circ. Says Teva Inhaler Patents Can't Be In Orange Book
- Hagens Berman Settles Suit Over Effexor Deal Atty Fees
- Nippon Owes $115M In Muscular Dystrophy IP Fight, Jury Says
- The Most Significant Trade Secrets Cases Of 2024
- Top Product Liability Cases Of 2024
- Psychedelics Law Reformers Hit Multiple Setbacks In 2024
- Reviewing 2024's Crucial Patent Law Developments
- Fla. Labs Appeal $7.3M Conn. Jury Verdict Favoring Cigna
- Top Privacy & Cybersecurity Developments Of 2024
- 7th Circ. Upholds $900K Punitive Damages Award In TM Case
- Capital Markets Attorneys Ready For Reset After Bumpy 2024
- Fixing Up Cars Makes Me A Better Lawyer
- Ex-Biopharma Exec Settles SEC Insider Trading Claim
- Judge Says Some Paraquat Plaintiffs Being Left In Dark
- PhRMA Wins Bid To Halt W.Va. Drug Discount Expansion Law
- FTC Says PBMs Can't Get Preliminary Block In Insulin Case
- Foley Adds Tech, Life Sciences Partner From IP Boutique
- Judge Wrongly Axed $107M IP Verdict, Pfizer Tells Fed. Circ.
- Biotech Co. Hid Eye Drug's Safety Risks, Investor Says
- Medical Supplies Giant, Drone Operator File Confidential IPOs
- McKesson Urges Justices To Keep Hobbs Act's 'Exclusivity'
- Medical Device Investors Get Final OK On $15M Deal
- Generic-Drug Cos. Get State AGs' Trial Order Flipped
- Labcorp Settles Competition Suit Against Ex-Sales Exec
- FDA Declaration May Restart Compounders' Shortage Suit
- Fresenius Loses Invalidity Argument In Nausea Drug IP Fight
- Making The Pitch To Grow Your Company's Legal Team
- Data Privacy Landscape After Mass. Justices' Wiretap Ruling
- Philips CPAP Suits Against SoClean Tossed From MDLs
- Pharma Trial Consultant To Pay SEC $3M Over Insider Trading
- Vaxart Investors Win Class Cert. Over COVID Shot On 2nd Try
- Patent Limits For Biosimilar Litigation Lands In Spending Bill
- FDA's Gastro Drug Fast-Track Denial Survives DC Circ.
- J&J Unit Beats Schizophrenia Drug IP Challenge On Remand
- State AGs, Generic Cos. Fight Over Price-Fixing Trial Order
- Judge Eyes Limits To Medical Device Co.'s Poaching Verdict
- The Future Of GLP-1 Policy After Drug Shortage Ends
- CVS Fueled Opioid Epidemic In Rush For Profits, Feds Say
- Amgen Hit With $50M Infringement Verdict Over Leukemia Drug
- FTC Wants Express Scripts' Defamation Suit Tossed
- Using Contracts As Evidence Of Trade Secret Protection
- RJ Reynolds Asks Justices To Toss Forum Shopping Argument
- SiteOne Gets $100M To Advance Non-Opioid Pain Treatments
- 11th Circ. Urged To Block Abortion Clinic Buffer Zone Law
- Laser Maker Loses Bid To Trim Patent Suit In Mass.
- Express Scripts, OptumRx Can't Ditch LA County Opioid Suit
- Sandoz Cuts $275M Deal For More Price-Fixing Claims
- Stanford Profs Say Roche's Trade Secret Claims Time-Barred
- House GOP Asks CVS How Its PBM Treats Smaller Pharmacies
- The Biggest Georgia Legal Developments Of 2024
- Feds Intervene In $200M FCA Case Against CVS
- Drug Co. Investor Sues In Del. Over $140M Insider Windfall
- When US Privilege Law Applies To Docs Made Outside The US
- Looking For Patterns In Pharmaceuticals' Use Of AI Patents
- Ginkgo Bioworks Investors Get Final OK Of $17.8M Settlement
- Becton Dickinson To Pay SEC $175M Over Pump Claims
- 11th Circ. Appears Wary Of Doc's New Trial Bid In $27.5M Case
- The Biggest Patent Decisions Of 2024
- The State Of USPTO Rulemaking At The End Of Vidal's Term
- Allele, Regeneron Settle COVID Treatment Patent Suit
- Supreme Court Rejects Salix Appeal In IBS Drug Case
- 2024 IPO Market Trends, And What To Expect Next Year
- With Legal Battle Looming, Neb. Legalizes Medical Marijuana
- Medical Device Co. Brass Hid SPAC's True Value, Suit Says
- Pharma Co. Brass Face Investor Suit Over Drug Trial Probe
- J&J Unit Deemed Family Duties A 'Distraction,' Suit Says
- What's Left In $400M Skinny Label Row? A Lot, Court Says
- Pa. Contractor Hit With $4.2M Verdict In Pot Software Row
- Sexual Abuse, Price-Gouging Bills Clear Michigan Senate
- Feds Narrow Drug Case Against Wife Of Convicted Drexel Prof
- Philly Atty Gets Harsher Discipline In NJ For Pill Mill Conviction
- Taxation With Representation: Kirkland, Davis Polk, Wachtell
- What 2024 Trends In Marketing, Comms Hiring Mean For 2025
- McKinsey To Pay $650M For Work With Opioid Maker Purdue
- Moderna Fires Back With Counterclaims In GSK RSV Vax Suit
- Align Tech's $27.5M Antitrust Deal Hits Nerve With Judge
- Pharma Co. Says Federal Court Must Weigh Atty Fee Bid
- Medicare Could Lose Billions From 'Patent Abuse,' Group Says
- Bausch And Lomb Says Potential Sale In The Works
- Wash. Justices OK Tax Break For Pharmacy Benefits Manager
- J&J Shampoo Contamination Suit Sent Down The Drain
- MOVEit Data Breach MDL Survives Dismissal Bid
- How Trump's Tariff Promises May Play Out In 2nd Term
- Cooley Wins Bid To Arbitrate Fla. Malpractice Suit
- Group Running Makes Me A Better Lawyer
- Montana Justices Uphold Temporary Block On Trans Care Ban
- AADI Enlists NY Court To Enforce Cancer Drug Award
- Ga. Judge Refuses To Reconsider Toss Of Patient Data Suit
- High Court Bar's Future: Haynes Boone's Daniel Geyser
- Neb. Medical Pot Legalization Hit With New Legal Challenge
- 6 Changes I Would Make If I Ran A Law School
- Predictions For Trump Antitrust Enforcement Of Life Sciences
- Kirkland-Led Patient Square Pays $4.1B For Animal Health Co.
- Md. Jury Convicts Ex-Biotech Execs On Some Fraud Counts
- Paul Hastings Says Biz Waived Privilege On Malpractice Docs
- Bristol-Myers Said To Renege On $450M Milestone Promise
- Judge Won't Cull EpiPen Antitrust Action Against Mylan
- PTAB Grapples With MRNA History In COVID Vax Dispute
- 9th Circ. Says Idaho Can't 'Veto' Federal Law In Abortion Row
- Ex-CEO Argues Arbitrator's Failure To Disclose Sinks Award
- FTC's Holyoak Says Chair OK With Some Cartels
- Beasley Allen Told To Give Update On J&J Discovery
- Nutraceutical Patent Insights As Market Heats Up
- Eli Lilly Says Tampa Health Biz Can't 'Pass The Buck' In TM Suit
- Labcorp Accuses Ex-Sales Exec Of Stealing Customers
- BioNTech, Pfizer Rival Wants Party Flip In COVID Vax IP Fight
- Ohio Justices Reject Opioid Nuisance Claims In $650M Appeal
- Firms Still Have The Edge In Lateral Hiring, But Buyer Beware
- Akin Gump 'Totally Messed Up' With Texts, Vaxart Judge Says
- Intellia Can't Escape Patent Suit Over $100M Regeneron Deal
- 9th Circ. Tosses Regal Cinemas' COVID Coverage Suit
- Condom Co. Says Rival Owes $744K In 'Naked' IP Dispute
- What 2024 Election Means For Drugs, Medicare And Medicaid
- UCLA Student Sues Doctors Over Transgender Misdiagnosis
- Prevagen Maker Ordered To Cease Memory Claims
- High Court Won't Hear Zimmer Biomet Royalties Fight
- Think Like A Lawyer: 1 Type Of Case Complexity Stands Out
- SEC Says Market Forecaster Ran Biotech Pump-And-Dump
- Philly Jury Clears B. Braun In Cancer Emissions Case
- Judge Denies Publix Bid To Appeal Opioid Coverage Ruling
- Galderma Can't Undo Lupin's Skin Drug Win At Fed. Circ.
- Google Must Face Trimmed BIPA Suit Over IBM Dataset
- 9th Circ. Won't Revisit CR Bard's Patent Misuse Win
- AngioDynamics Port Defect Caused Infection, Ga. Man Says
- What Bisphenol S Prop 65 Listing Will Mean For Industry
- Anthem Wants Testing Lab's $3.8M Suit Axed Or Split Up
- Creditor Says Failed Solar Biotech Bidder Shouldn't Get Fee
- Philips Medical Monitoring Deal, $4.8M Fees Get Final OK
- Fed. Circ. Ruling Shows Importance Of Trial Expert Specificity
- Husband Of Ex-Takeda Exec Convicted For $2M Invoice Fraud
- UK Litigation Roundup: Here's What You Missed In London
- Think Like A Lawyer: Note 3 Simple Types Of Legal Complexity
- Fed. Circ. Grapples With Injunctions On Eylea Biosimilars
- IP Forecast: PTAB To Hear Pfizer Fight Over COVID-19 Patents
- Fla. Labs Say Cigna's Trial 'Confession' Erases $7.3M Verdict
- Gov't Efficiency Push Is A 'New Day,' House Speaker Says
- FINRA Fines Firm $900K Over SPAC Underwriting Fee Issues
- Abbott Accused Of 'Last-Ditch Effort' To Halt Formula Suit
- Quest Ex-Workers Ask 3rd Circ. To Revive 401(k) Suit
- Justices Mull Sex-Based Classification In Trans Law Case
- SpaceX Seeks Astronomical $350B Value, And More Rumors
- FDA Warns 115 Retailers Over Unauthorized E-Cigarettes
- Gardening Makes Me A Better Lawyer
- Insulet Wins $452M In Trade Secret Theft Trial
- Withers IP Partners Hop To Sullivan & Worcester
- Novartis Fails To Stop Generic Drug Release At Fed. Circ.
- Jackson's 'Quite Worried' About Equal Protection Precedent
- JSR Wins As Fed. Circ. Axes Cytiva Antibody Isolation Patents
- Colo. Co.'s Alleged Kickback Scheme Ends In $2M Settlements
- DEA Judge Sets Pot Rescheduling Hearings
- Fed. Circ. Judge Condemns 'Nonsense' Law In Antibody Fight
- Takeda Exec Duped Beau Into $2M Fraud, Jury Told
- Justices Seem To Back Ban On Transgender Youth Care
- Litigation Inspiration: Reframing Document Review
- Mich. AG Deal, NIH 4th Circ. Win And X Corp Bid In HIPAA Row
- Calif. Unveils Reproductive Rights Bills To Prep For Trump
- SEC Says Biopharma's Cooperation Helped It Avoid Penalty
- J&J's Neosporin Forever Discolored Man's Groin, Suit Says
- $1B Sandoz Placeholder Bid Needs More Support, Judge Says
- USPTO Abandons Polarizing Proposal Over Double Patenting
- Vidal Aimed To Put USPTO Rulemaking In The Spotlight
- Key Takeaways From FDA's Latest Social Media Warnings
- FDA Issues Guidance On Potential Infant Formula Shortages
- 4 Mass. State Court Rulings You May Have Missed In Nov.
- VA Announces Study On MDMA-Assisted Therapy For Vets
- Expect More State Scrutiny Of PE In Healthcare M&A
- Declaring Unexpected Results: Pitfalls For Rule 132 At PTAB
- House COVID-19 Probe Points to China 'Lab Leak'
- Judge Isn't Seeing 'Good Faith' Compliance In Probiotic Feud
- Justices Seem Inclined To Back FDA Block Of Flavored Vapes
- Investor Alleges Medical Device Co. Misled On FDA Clearance
- Hagens Berman Sued For Slice Of Atty Fee From Effexor Deal
- Chancery OKs $21M Deal To End Gene Co. Class Suit
- Fla. Tribe Sues Eli Lilly, CVS, Others Over Insulin Price-Fixing
- Heritage's $10M Generic Drugs Deal With AGs Gets 1st OK
- IP Ruling Likely To Limit Arguments Against Qualified Experts
- How Boards And Officers Should Prep For New Trump Admin
- DEA Asserts Its Role As Proponent Of Pot Rescheduling Plan
- Ex-Parexel Worker Says Vax Rule Lacked 'Informed Consent'
- Shipping Industry Braces For Waves Of New Trump Tariffs
- Co-Worker's Affair Isn't Harassment, Research Co. Tells Court